Evidence map›Paper›PMID 36077598›Full record

ArticleInternational journal of molecular sciences2022

Proteomics Profiling of Osteoporosis and Osteopenia Patients and Associated Network Analysis.

Mysoon M Al-Ansari, Shereen M Aleidi, Afshan Masood, Eman A Alnehmi, Mai Abdel Jabar, Maha Almogren, Mohammed Alshaker, Hicham Benabdelkamel, Anas M Abdel Rahman

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Mysoon M Al-AnsariDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Shereen M AleidiDepartment of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0001-9222-464X
Afshan MasoodProteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.ORCID 0000-0001-8082-9326
Eman A AlnehmiDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Mai Abdel JabarMetabolomics Section, Department of Clinical Genomics, Center for Genomics Medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh 11211, Saudi Arabia.
Maha AlmogrenMetabolomics Section, Department of Clinical Genomics, Center for Genomics Medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh 11211, Saudi Arabia.
Mohammed AlshakerDepartment of Family Medicine and Polyclinic, King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia.
Hicham BenabdelkamelProteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.ORCID 0000-0001-9745-2959
Anas M Abdel RahmanMetabolomics Section, Department of Clinical Genomics, Center for Genomics Medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh 11211, Saudi Arabia.ORCID 0000-0002-9527-9424
King Faisal Specialist Hospital & Research Centre · SAKing Saud University · SAAlfaisal University · SAMemorial University of Newfoundland · CAUniversity of Jordan · JO

Funding

The National Plan for Science, Technology and Innovation (MAARIFAH), King Abdulaziz City for Science and Technology 08-MED513-02
6 · The paper itself

Abstract

Bone mass reduction due to an imbalance in osteogenesis and osteolysis is characterized by low bone mineral density (LBMD) and is clinically classified as osteopenia (ON) or osteoporosis (OP), which is more severe. Multiple biomarkers for diagnosing OP and its progression have been reported; however, most of these lack specificity. This cohort study aimed to investigate sensitive and specific LBMD-associated protein biomarkers in patients diagnosed with ON and OP. A label-free liquid chromatography-mass spectrometry (LC-MS) proteomics approach was used to analyze serum samples. Patients' proteomics profiles were filtered for potential confounding effects, such as age, sex, chronic diseases, and medication. A distinctive proteomics profile between the control, ON, and OP groups (Q

Indexed as

OsteoporosisProteomicsBiomarkersBone DensityChromatography, LiquidCohort StudiesHumansRNA-Binding ProteinsBiomarkersMEX3B protein, humanRNA-Binding Proteinsbone mineral density (BMD)mass spectrometryosteopeniaosteoporosisproteomics

Identifiers

PMID36077598
PMCPMC9456664
OpenAlexW4294733363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.